In adults with moderate-to-severe pemphigus on prednisone, adding weekly subcutaneous efgartigimod did not improve complete remission on minimal prednisone by week 30 in pemphigus vulgaris vs placebo (35.5% vs 30.3%; OR 1.19, P=0.60). AEs 89.1% vs 76.0%.
RCTn = 222
Joly et al. Efficacy and safety of subcutaneous efgartigimod with prednisone in moderate-to-severe pemphigus (ADDRESS): a global, phase III, randomised controlled, double-blind trial